Sun Pharma Advanced Research Company (SPARC) has reported that its licensee has received an approval from the Drug Controller General of India (DCGI) for Paclitaxel Injection Concentrate for Nanodispersion (PICN), indicated for the treatment of metastatic breast cancer. SPARC has licensed Sun Pharmaceutical Industries (SPIL) or its assignee to manufacture, promote and distribute PICN in the Indian market. As a part of the arrangement, SPARC is eligible for milestone and royalty income.For more information call- 0731-6642300 or Visit https://www.epicresearch.co/
No comments:
Post a Comment